LAS VEGAS, July 13, 2024 /PRNewswire/ -- JanOne Inc.
(Nasdaq: JAN), a multidisciplinary organization with a focus on
fintech and healthcare, confirmed today that, as of market open on
Monday, July 15, 2024, the Company's
new name will be "ALT5 Sigma Corporation" and its Nasdaq common
stock ticker symbol will change to "ALTS". This will replace the
Company's current ticker symbol "JAN". Further, the Company's
website address will change from "janone.com" to
"alt5sigma.com."
The Company's change of name, ticker symbol, and website address
aligns with the Company's realignment to focus on its recently
acquired, ALT5 Sigma fintech as its core engine for revenue
growth.
This realignment and changes in corporate name and the ticker
symbol were previously announced on July 10,
2024. No action by the Company's stockholders is required
with respect to the ticker symbol change. The Company's CUSIP
number and transfer agent will remain unchanged.
Marking the changes confirmed today, Tony Isaac, Company CEO, observed, "We are
pleased to complete the changes to our name and ticker symbol as
the initial steps in our previously announced diversification into
fintech, while keeping our biotech's trajectory on track, all for
the benefit of our stockholders."
About JanOne/ALT5 Sigma
The Company is a unique Nasdaq-listed multidisciplinary
organization with a focus on healthcare and fintech. The Company is
one of the constituents of the Russell Microcap Index, starting
June 28, 2024.
Through its fintech activities, the Company provides next
generation blockchain-powered technologies to enable a migration to
a new global financial paradigm for the trading, clearing,
settlement, payment, and custodianship of digital instruments.
Through its fintech subsidiaries, the Company offers two main
platforms to its customers: "ALT5 Pay" and "ALT5 Prime". The
subsidiaries processed over US$1.2
billion in cryptocurrency transactions in 2023.
ALT5 Pay is a crypto-currency payment gateway that enables
registered and approved global merchants to accept and make
crypto-currency payments or to integrate the ALT5 Pay payment
platform into their application or operations using the plugin with
WooCommerce and or ALT5 Pay's checkout widgets and APIs. Merchants
have the option to convert to fiat currency (s) automatically or to
receive their payment in digital assets.
ALT5 Prime is an electronic over-the-counter trading platform
that enables registered and approved customers to buy and sell
digital assets. Customers can purchase digital assets with fiat
and, equally, can sell digital assets and receive fiat. ALT5 Prime
is available through a browser-based access mobile phone
application named "ALT5 Pro" that can be downloaded from the Apple
App Store, from Google Play, through ALT5 Prime's FIX API, as well
as through Broadridge Financial Solutions' NYFIX gateway for
approved customers.
Through its biotech activities, the Company is developing
innovative, actionable solutions intended to help end the opioid
crisis. The Company is dedicated to funding resources toward
innovation, technology, and education to find a key resolution to
the national opioid epidemic, which is one of the deadliest and
most widespread in the nation's history. Its drugs in the clinical
trial pipeline have shown promise for their innovative targeting of
the causes of pain as a strategic option for physicians averse to
exposing patients to addictive opioids.
Forward Looking Statements
This press release contains statements that are forward-looking
statements as defined within the Private Securities Litigation
Reform Act of 1995, including, but not limited to, statements
relating to the profitability and prospective growth of ALT5's
platforms and business, that may include, but are not limited to,
international currency risks, third-party or customer credit risks,
liability claims stemming from ALT5's services, and technology
challenges for future growth or expansion. This press release also
contains statements and links relating to risks that JAN 101 will
treat PAD, that JAN 123 will treat CRPS, the timing of the
commencement of clinical trials, that the FDA will permit approval
through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101
will immediately disrupt the PAD market, and other statements,
including words such as "continue", "expect", "intend", "will",
"hope", "should", "would", "may", "potential", and other similar
expressions. Such statements reflect the Company's current view
with respect to future events, are subject to risks and
uncertainties, and are necessarily based upon a number of estimates
and assumptions that, while considered reasonable by the Company,
are inherently subject to significant business, economic,
competitive, political, and social uncertainties, and
contingencies.
Many factors could cause the Company's actual results,
performance, or achievements to be materially different from any
future results, performance or achievements described in this press
release. Such factors could include, among others, those detailed
in the Company's periodic reports filed with the Securities and
Exchange Commission (the "SEC"). Should one or more of these risks
or uncertainties materialize, or should the assumptions set out in
the section entitled "Risk Factors" in the Company's filings with
the SEC underlying those forward-looking statements prove
incorrect, actual results may vary materially from those described
herein. These forward-looking statements are made as of the date of
this press release and the Company does not intend, and does not
assume any obligation, to update these forward-looking statements,
except as required by law. The Company cannot assure that such
statements will prove to be accurate as actual results and future
events could differ materially from those anticipated in such
statements. Individuals are cautioned that forward-looking
statements are not guarantees of future performance and accordingly
investors are cautioned not to put undue reliance on
forward-looking statements due to the inherent uncertainty
therein.
Media Contact Investor Relations
IR@alt5sigma.com
1-800-400-2247
Logo -
https://mma.prnewswire.com/media/973662/JanOne_With_4C_TM_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/janone-confirms-name-change-to-alt5-sigma-corporation-and-new-ticker-symbol-to-alts-302196185.html